{
    "clinical_study": {
        "@rank": "100694", 
        "arm_group": [
            {
                "arm_group_label": "amdoxovir 300 mg bid", 
                "arm_group_type": "Experimental", 
                "description": "in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3"
            }, 
            {
                "arm_group_label": "amdoxovir 500 mg bid", 
                "arm_group_type": "Experimental", 
                "description": "in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3"
            }, 
            {
                "arm_group_label": "tenofovir DF 300 mg qd", 
                "arm_group_type": "Active Comparator", 
                "description": "in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a double-blind Phase 2a study to test the safety and efficacy of an investigational\n      HIV drug, amdoxovir (300 mg or 500 mg twice daily) compared with tenofovir DF 300 mg once\n      daily in HIV-1 infected antiretroviral therapy-experienced subjects who are currently\n      failing antiretroviral therapy. There are three treatment groups (N=45). Subjects will be\n      randomized to receive either amdoxovir 300 mg twice daily (n=15) or amdoxovir 500 mg twice\n      daily (n=15) or tenofovir DF 300 mg once daily (n=15); each in combination with zidovudine\n      300 mg twice daily.\n\n      The study will assess initially amdoxovir (300 mg or 500 mg twice daily) or tenofovir DF 300\n      mg once daily, both in combination zidovudine 300 mg twice daily plus failing third drug,\n      but then with lopinavir/ritonavir (400 mg/100 mg twice daily) after Week 2. Subjects who\n      received amdoxovir (300 mg or 500 mg twice daily) and benefited from the drug may choose to\n      enroll in the 36-week open-label study."
        }, 
        "brief_title": "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Human Immunodeficiency Virus Infection", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female \u2265 18 years old with HIV-1 RNA \u2265 2,000 copies/mL and currently failing\n             therapy.\n\n          -  Has M184I/V mutation in addition to 0-2 thymidine analog mutations (TAMs) at\n             screening.\n\n          -  Agree to be abstinent or use two reliable forms of contraception (for females) and\n             one form for men when participating in sexual activity that could result in\n             pregnancy.\n\n        Exclusion Criteria:\n\n          -  Current or recent (last 30 days of study entry) AIDS defining diseases.\n\n          -  Genotypic resistance testing at screening indicating K65R, L74V, Q151M mutation.\n\n          -  Prior exposure to lopinavir/ritonavir or amdoxovir.\n\n          -  Impaired hepatic function (ALT > 5 x ULN).\n\n          -  Women who are pregnant or breast feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737359", 
            "org_study_id": "RFSP-AMDX-2010"
        }, 
        "intervention": [
            {
                "arm_group_label": "amdoxovir 300 mg bid", 
                "description": "2 x 150 mg capsules bid", 
                "intervention_name": "amdoxovir 300 mg bid", 
                "intervention_type": "Drug", 
                "other_name": [
                    "DAPD", 
                    "AMDX"
                ]
            }, 
            {
                "arm_group_label": "amdoxovir 500 mg bid", 
                "description": "2 x 250 mg capsules bid", 
                "intervention_name": "amdoxovir 500 mg bid", 
                "intervention_type": "Drug", 
                "other_name": [
                    "DAPD", 
                    "AMDX"
                ]
            }, 
            {
                "arm_group_label": "tenofovir DF 300 mg qd", 
                "description": "1 x 300 mg tablet once daily", 
                "intervention_name": "tenofovir DF 300 mg qd", 
                "intervention_type": "Drug", 
                "other_name": "Viread"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Tenofovir", 
                "Tenofovir disoproxil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "amdoxovir", 
            "zidovudine", 
            "tenofovir DF", 
            "HIV", 
            "HAART", 
            "antiretroviral"
        ], 
        "lastchanged_date": "March 27, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Rosario", 
                        "country": "Argentina", 
                        "state": "Santa Fe", 
                        "zip": "S2000CXP"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rosario", 
                        "country": "Argentina", 
                        "state": "Santa Fe", 
                        "zip": "S2000PBJ"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "C1426EGR"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "C1405CKC"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "C1141ACG"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "C1202ABB"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Argentina"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase IIa, Randomized, Double-blind, Active-controlled, 12-week Study of Amdoxovir (Two Doses) Versus Tenofovir DF, in Combination With Zidovudine in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.", 
        "overall_official": {
            "affiliation": "RFS Pharma", 
            "last_name": "Luz Pascual, MD MPH", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "HIV-1 viral load", 
                "safety_issue": "No", 
                "time_frame": "change from baseline to Week 2"
            }, 
            {
                "measure": "Safety and Tolerability- Incidence of adverse events and laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "number and frequency from baseline through Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737359"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "HIV-1 viral load", 
                "safety_issue": "No", 
                "time_frame": "change from baseline to Weeks 4, 8 and 12"
            }, 
            {
                "measure": "Changes in Immunologic Function (CD4 cell counts)", 
                "safety_issue": "No", 
                "time_frame": "changes from baseline  to Weeks 4, 8 and 12"
            }
        ], 
        "source": "RFS Pharma, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RFS Pharma, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}